<p>药明康德（NYSE:PRGO - 获取免费报告）在周六发布的报告中被 StockNews.com 的分析师从 “买入” 评级下调至 “持有” 评级。</p>
<p>其他股票分析师最近也对该公司发布了报告。Piper Sandler 将药明康德的评级从 “增持” 下调至 “中性”，并在 1 月 6 日的研究报告中将其目标价从 34.00 美元下调至 27.00 美元。Jefferies Financial Group 在 9 月 23 日的研究报告中重申了 “持有” 评级，并将药明康德的目标价设定为 30.00 美元（之前为 50.00 美元）。最后，Canaccord Genuity Group 在 9 月 30 日的研究报告中重申了 “买入” 评级，并将药明康德的目标价设定为 42.00 美元。三位研究分析师对该股票给予了 “持有” 评级，两位分析师给予了 “买入” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “持有”，共识目标价为 35.00 美元。</p>
<p><strong>获取我们最新的 PRGO 股票报告</strong></p>
<h2>药明康德股价下跌 2.6%</h2>
<p>PRGO 股票在周五开盘价为 24.41 美元。该股票的 50 日移动平均线为 26.77 美元，200 日移动平均线为 26.81 美元。该公司的债务与股本比率为 0.94，速动比率为 1.77，流动比率为 2.56。该公司的市值为 33.3 亿美元，市盈率为-20.86，贝塔值为 0.53。药明康德的 52 周低点为 23.89 美元，52 周高点为 33.96 美元。</p>
<p>药明康德（NYSE:PRGO - 获取免费报告）最近在 11 月 6 日发布了其财报。该公司报告季度每股收益（EPS）为 0.81 美元，符合分析师的共识预期 0.81 美元。药明康德的股本回报率为 7.38%，净利润率为-3.64%。该公司在本季度的收入为 10.9 亿美元，而共识预期为 11.2 亿美元。去年同期，该公司每股收益为 0.64 美元。该公司本季度的收入同比下降了 3.2%。研究分析师预计药明康德在当前财政年度的每股收益将达到 2.56 美元。</p>
<h2>内部人士买卖</h2>
<p>在其他新闻中，董事 Jeffrey B. Kindler 在 12 月 9 日的交易中出售了 17,598 股公司的股票。该股票以 28.27 美元的平均价格出售，总价值为 497,495.46 美元。出售后，该董事现在直接持有 5,409 股公司股票，价值 152,912.43 美元。这代表了他们持有的股票减少了 76.49%。该出售在与证券交易委员会的法律文件中披露，该文件可通过 SEC 网站获取。当前 0.70% 的股票由公司内部人士持有。</p>
<h2>对药明康德的对冲基金看法</h2>
<p>几家大型投资者最近增加或减少了对 PRGO 的持股。Wealth Enhancement Advisory Services LLC 在第四季度将其在药明康德的持股增加了 2.1%。Wealth Enhancement Advisory Services LLC 现在持有 21,617 股公司股票，价值 567,000 美元，此前在上个季度又购买了 436 股。Voisard Asset Management Group Inc.在第三季度将其在药明康德的持股增加了 9.7%。Voisard Asset Management Group Inc.现在持有 5,100 股公司股票，价值 134,000 美元，此前在上个季度又购买了 450 股。Central Pacific Bank Trust Division 在第四季度将其在药明康德的持股增加了 33.3%。Central Pacific Bank Trust Division 现在持有 2,000 股公司股票，价值 51,000 美元，此前在此期间又购买了 500 股。Creative Planning 在第三季度将其在药明康德的持股增加了 3.7%。Creative Planning 现在持有 18,477 股公司股票，价值 485,000 美元，此前在此期间又购买了 661 股。最后，亚利桑那州退休系统在第二季度将其在药明康德的持股增加了 1.9%。亚利桑那州退休系统现在持有 37,939 股公司股票，价值 974,000 美元，此前在此期间又购买了 699 股。当前 95.91% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>药明康德公司简介</h2>
<p>（获取免费报告）</p>
<p>药明康德公司提供非处方健康和保健解决方案，以提升个人在美国、欧洲和国际上的福祉。它通过消费者自我护理美洲和消费者自我护理国际两个部门运营。该公司开发、制造、营销和分销自我护理消费品，如上呼吸道产品，包括止咳药、祛痰药以及鼻窦和过敏缓解药；营养产品，包括婴儿配方奶粉和营养饮料；消化健康产品，包括抗酸药、止泻药和抗胃灼热药；止痛和助眠产品，包括止痛药和退烧药；以及口腔护理产品，包括牙刷、牙刷替换头、牙线、牙线棒、美白产品和牙刷保护套。</p>
<h2>精选文章</h2>
<ul>
<li>我们更喜欢的五只股票比药明康德更好</li>
<li>哪些华尔街分析师最准确？</li>
<li>向前推进：Lucid 的销售增长和 Gravity SUV 的影响</li>
<li>如何在 7 个步骤中投资大麻股票</li>
<li>为什么亚马逊的下一个财报可能会引发股票突破</li>
<li>10 美元以下的最佳股票</li>
<li>有了这种数据，美联储今年不会降息</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在药明康德吗？</h2>
<p>在你考虑药明康德之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而培瑞克并不在名单上。</p>
<p>虽然培瑞克目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

培瑞克

<p>培瑞克（NYSE:PRGO）被 StockNews.com 从 “买入” 评级下调至 “持有” 评级。其他分析师，包括 Piper Sandler 和 Jefferies Financial Group，也调整了对该股票的评级和目标价格。目前，培瑞克的共识评级为 “持有”，目标价格为 35.00 美元。该股票开盘价为 24.41 美元，下跌 2.6%，市值为 33.3 亿美元。最近的财报显示每股收益为 0.81 美元，与预期相符，但收入同比下降了 3.2%。还注意到内部交易活动，一位董事出售了大量股份</p>

<p>Perrigo (NYSE:PRGO - Get Free Report) was downgraded by analysts at StockNews.com from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report issued on Saturday.</p>
<div class="lb-trans"><p>药明康德（NYSE:PRGO - 获取免费报告）在周六发布的报告中被 StockNews.com 的分析师从 “买入” 评级下调至 “持有” 评级。</p>
</div><p>Other equities analysts also recently issued reports about the company. Piper Sandler downgraded Perrigo from an &#34;overweight&#34; rating to a &#34;neutral&#34; rating and dropped their target price for the company from $34.00 to $27.00 in a research report on Monday, January 6th. Jefferies Financial Group reiterated a &#34;hold&#34; rating and issued a $30.00 price objective (down previously from $50.00) on shares of Perrigo in a research note on Monday, September 23rd. Finally, Canaccord Genuity Group reiterated a &#34;buy&#34; rating and issued a $42.00 price objective on shares of Perrigo in a research note on Monday, September 30th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of &#34;Hold&#34; and a consensus target price of $35.00.</p>
<div class="lb-trans"><p>其他股票分析师最近也对该公司发布了报告。Piper Sandler 将药明康德的评级从 “增持” 下调至 “中性”，并在 1 月 6 日的研究报告中将其目标价从 34.00 美元下调至 27.00 美元。Jefferies Financial Group 在 9 月 23 日的研究报告中重申了 “持有” 评级，并将药明康德的目标价设定为 30.00 美元（之前为 50.00 美元）。最后，Canaccord Genuity Group 在 9 月 30 日的研究报告中重申了 “买入” 评级，并将药明康德的目标价设定为 42.00 美元。三位研究分析师对该股票给予了 “持有” 评级，两位分析师给予了 “买入” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “持有”，共识目标价为 35.00 美元。</p>
</div><p><strong>Get Our Latest Stock Report on PRGO</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 PRGO 股票报告</strong></p>
</div><h2>Perrigo Trading Down 2.6 %</h2>
<div class="lb-trans"><h2>药明康德股价下跌 2.6%</h2>
</div><p>Shares of PRGO stock opened at $24.41 on Friday. The stock's fifty day moving average is $26.77 and its two-hundred day moving average is $26.81. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.77 and a current ratio of 2.56. The firm has a market capitalization of $3.33 billion, a P/E ratio of -20.86 and a beta of 0.53. Perrigo has a fifty-two week low of $23.89 and a fifty-two week high of $33.96.</p>
<div class="lb-trans"><p>PRGO 股票在周五开盘价为 24.41 美元。该股票的 50 日移动平均线为 26.77 美元，200 日移动平均线为 26.81 美元。该公司的债务与股本比率为 0.94，速动比率为 1.77，流动比率为 2.56。该公司的市值为 33.3 亿美元，市盈率为-20.86，贝塔值为 0.53。药明康德的 52 周低点为 23.89 美元，52 周高点为 33.96 美元。</p>
</div><p>Perrigo (NYSE:PRGO - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported $0.81 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.81. Perrigo had a positive return on equity of 7.38% and a negative net margin of 3.64%. The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same period last year, the company earned $0.64 EPS. The company's revenue for the quarter was down 3.2% on a year-over-year basis. Research analysts expect that Perrigo will post 2.56 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>药明康德（NYSE:PRGO - 获取免费报告）最近在 11 月 6 日发布了其财报。该公司报告季度每股收益（EPS）为 0.81 美元，符合分析师的共识预期 0.81 美元。药明康德的股本回报率为 7.38%，净利润率为-3.64%。该公司在本季度的收入为 10.9 亿美元，而共识预期为 11.2 亿美元。去年同期，该公司每股收益为 0.64 美元。该公司本季度的收入同比下降了 3.2%。研究分析师预计药明康德在当前财政年度的每股收益将达到 2.56 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖</h2>
</div><p>In other news, Director Jeffrey B. Kindler sold 17,598 shares of the company's stock in a transaction on Monday, December 9th. The stock was sold at an average price of $28.27, for a total value of $497,495.46. Following the sale, the director now directly owns 5,409 shares in the company, valued at $152,912.43. This represents a 76.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through the SEC website. 0.70% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Jeffrey B. Kindler 在 12 月 9 日的交易中出售了 17,598 股公司的股票。该股票以 28.27 美元的平均价格出售，总价值为 497,495.46 美元。出售后，该董事现在直接持有 5,409 股公司股票，价值 152,912.43 美元。这代表了他们持有的股票减少了 76.49%。该出售在与证券交易委员会的法律文件中披露，该文件可通过 SEC 网站获取。当前 0.70% 的股票由公司内部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Perrigo</h2>
<div class="lb-trans"><h2>对药明康德的对冲基金看法</h2>
</div><p>Several large investors have recently added to or reduced their stakes in PRGO. Wealth Enhancement Advisory Services LLC grew its stake in shares of Perrigo by 2.1% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 21,617 shares of the company's stock valued at $567,000 after buying an additional 436 shares in the last quarter. Voisard Asset Management Group Inc. lifted its holdings in shares of Perrigo by 9.7% in the 3rd quarter. Voisard Asset Management Group Inc. now owns 5,100 shares of the company's stock worth $134,000 after purchasing an additional 450 shares during the last quarter. Central Pacific Bank Trust Division increased its position in Perrigo by 33.3% in the 4th quarter. Central Pacific Bank Trust Division now owns 2,000 shares of the company's stock valued at $51,000 after acquiring an additional 500 shares during the period. Creative Planning increased its position in shares of Perrigo by 3.7% during the 3rd quarter. Creative Planning now owns 18,477 shares of the company's stock valued at $485,000 after purchasing an additional 661 shares during the period. Finally, Arizona State Retirement System increased its position in shares of Perrigo by 1.9% during the 2nd quarter. Arizona State Retirement System now owns 37,939 shares of the company's stock valued at $974,000 after purchasing an additional 699 shares during the period. 95.91% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家大型投资者最近增加或减少了对 PRGO 的持股。Wealth Enhancement Advisory Services LLC 在第四季度将其在药明康德的持股增加了 2.1%。Wealth Enhancement Advisory Services LLC 现在持有 21,617 股公司股票，价值 567,000 美元，此前在上个季度又购买了 436 股。Voisard Asset Management Group Inc.在第三季度将其在药明康德的持股增加了 9.7%。Voisard Asset Management Group Inc.现在持有 5,100 股公司股票，价值 134,000 美元，此前在上个季度又购买了 450 股。Central Pacific Bank Trust Division 在第四季度将其在药明康德的持股增加了 33.3%。Central Pacific Bank Trust Division 现在持有 2,000 股公司股票，价值 51,000 美元，此前在此期间又购买了 500 股。Creative Planning 在第三季度将其在药明康德的持股增加了 3.7%。Creative Planning 现在持有 18,477 股公司股票，价值 485,000 美元，此前在此期间又购买了 661 股。最后，亚利桑那州退休系统在第二季度将其在药明康德的持股增加了 1.9%。亚利桑那州退休系统现在持有 37,939 股公司股票，价值 974,000 美元，此前在此期间又购买了 699 股。当前 95.91% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Perrigo Company Profile</h2>
<div class="lb-trans"><h2>药明康德公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.</p>
<div class="lb-trans"><p>药明康德公司提供非处方健康和保健解决方案，以提升个人在美国、欧洲和国际上的福祉。它通过消费者自我护理美洲和消费者自我护理国际两个部门运营。该公司开发、制造、营销和分销自我护理消费品，如上呼吸道产品，包括止咳药、祛痰药以及鼻窦和过敏缓解药；营养产品，包括婴儿配方奶粉和营养饮料；消化健康产品，包括抗酸药、止泻药和抗胃灼热药；止痛和助眠产品，包括止痛药和退烧药；以及口腔护理产品，包括牙刷、牙刷替换头、牙线、牙线棒、美白产品和牙刷保护套。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Perrigo</li>
<li>Which Wall Street Analysts are the Most Accurate?</li>
<li>Driving Forward: Lucid’s Growing Sales and Gravity SUV's Impact</li>
<li>How to invest in marijuana stocks in 7 steps</li>
<li>Why Amazon’s Next Earnings Could Trigger a Stock Breakout</li>
<li>Best Stocks Under $10.00</li>
<li>With This Kind of Data, The Fed Isn’t Cutting Rates This Year</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票比药明康德更好</li>
<li>哪些华尔街分析师最准确？</li>
<li>向前推进：Lucid 的销售增长和 Gravity SUV 的影响</li>
<li>如何在 7 个步骤中投资大麻股票</li>
<li>为什么亚马逊的下一个财报可能会引发股票突破</li>
<li>10 美元以下的最佳股票</li>
<li>有了这种数据，美联储今年不会降息</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Perrigo Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在药明康德吗？</h2>
</div><p>Before you consider Perrigo, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑药明康德之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Perrigo wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而培瑞克并不在名单上。</p>
</div><p>While Perrigo currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然培瑞克目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

培瑞克（纽约证券交易所代码：PRGO）被 StockNews.com 降级为持有评级